Laurus Labs Limited — PPTs, 30-04-2026: Investor Presentation

Laurus Labs delivered a strong FY26, with revenue up 23% to ₹6,813 Cr and net profit soaring 148% to ₹889 Cr (EPS ₹16.4). The CDMO division was a key growth driver, expanding 36% and now accounts for 31% of revenue. Affordable Medicines grew 18%.

The company is strategically investing in future growth, expanding CDMO capabilities with new modalities like Gene Therapy/ADC, including a planned cGMP facility, and a significant new 532-acre Vizag site with over $600 million investment. Recent developments include an operational Advanced Biologics Process Development lab and a new CAR-T GMP facility commissioned in March, tripling capacity.

Management highlights healthy operational leverage, with EBITDA up 64% to ₹1,826 Cr (26.8% margin), and a sharp reduction in Net Debt-to-EBITDA to 1.3x. Laurus continues its substantial capex roadmap, prioritizing ESG with targets for significant emission reductions by FY31.